09/678,554 -2- 5604-D1-01-SRE

This listing of claims will replace all prior versions, and listings, of claims in this application.

Listing of Claims:

Claim 1 (previously amended) A compound having the Formula I

wherein:

R^a, R^b, R^c are each independently C_1-C_6 alkyl or hydrogen;

R^d, R^e, R^f, and R^g are each independently C_1-C_6 alkyl, hydrogen, or phenyl;

Y is -O-, -N-, or -N-;
$\quad\quad\quad\quad$ |$\quad\quad$ |
$\quad\quad\quad\quad$ H$\quad\quad$ C_1-C_6 alkyl;

R^3 is

R^2 is

R^4 is aryl, substituted aryl, or C_1-C_6 alkyl; and

each n is independently 0 to 5, m is 2 to 4 or a pharmaceutically acceptable salt or prodrug form thereof.

Claim 2 (previously amended) The compound of Claim 1 wherein Y is -O-.

Claim 3 (previously amended) The compound of Claim 1 wherein

Y is $-\overset{\displaystyle |}{\underset{\displaystyle H}{N}}-$ or $-\overset{\displaystyle |}{\underset{\displaystyle CH_3}{N}}-$.

Claim 4 (previously amended) The compound of Claim 1 wherein R^a is hydrogen, R^b is methyl, and R^c is hydrogen.

Claim 5 (previously amended) The compound of Claim 1 wherein

R^3 is —$(CH_2)_n$—⟨◯⟩—O-benzyl.

Claim 6 (previously amended) The compound of Claim 1 wherein R^3

—$(CH_2)_n$—⟨◯⟩ .

Claims 7 and 8 (canceled).

Claim 9 (previously amended) The compound of Claim 1 wherein

R^2 is $-\overset{\displaystyle H}{\underset{\displaystyle H}{C}}-\underset{(CH_2)_m}{C}-$phenyl   or $-\overset{\displaystyle H}{\underset{\displaystyle H}{C}}-\underset{(CH_2)_m}{C}-$substituted phenyl.

Claim 10 (previously amended) The compound of Claim 9 wherein m of

$-\overset{\displaystyle H}{\underset{\displaystyle H}{C}}-\underset{(CH_2)_m}{C}-$phenyl   or $-\overset{\displaystyle H}{\underset{\displaystyle H}{C}}-\underset{(CH_2)_m}{C}-$substituted phenyl.

m is 3 or 4.

09/678,554   -4-   5604-D1-01-SRE

Claim 11 (previously amended) The compound of Claim 1 wherein R^3 is -$(CH_2)_n$-C_1-C_6 alkyl.

Claim 12 (previously amended) The compound of Claim 1 wherein

R^3 is ——(CH$_2$)——⟨○⟩—— OCH$_2$ ——pyridyl .

Claim 13 (canceled).

Claim 14 (currently amended) The compound ~~of:~~

~~[S-(R*,R*)]-[1-({2-(4-Benzyloxy-phenyl)-1-[(1-phenyl-~~
~~cyclopropyl-methyl)-carbamoyl]-ethyl}-methyl-carbamoyl)-2-(3H-imidazol-4-~~
~~yl)-ethyl]-carbamic acid benzyl ester;~~

[S-(R*,R*)]-[1-[(2-(4-Benzyloxy-phenyl)-1-{[1-(2-fluoro-phenyl)-
cyclopropylmethyl]-carbamoyl}ethyl)-methyl-carbamoyl]-2-(3H-imidazol-
4-yl)-ethyl]-carbamic acid benzyl ester ~~; and~~

~~[S-(R*,R*)]-[1-({2-(4-Benzyloxy-phenyl)-1-[(1-phenyl-~~
~~cyclobutylmethyl)-carbamoyl]-ethyl}-methyl-carbamoyl)-2-(3H-imidazol-4-yl)-ethyl]-carbamic~~
~~acid benzyl ester;~~ , or a pharmaceutically acceptable salt form thereof.

Claims 15-22 (canceled).

Claim 23 (previously added) A method of inhibiting smooth muscle proliferation in a mammal which has been subjected to injury of vascular tissue comprising administering to said mammal an amount of a compound of Claim 1 for a time and under conditions effective to sufficiently inhibit ras farnesyl transferase to inhibit said smooth muscle proliferation.

Claims 24 and 25 (canceled).